Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia

Adrien Contejean, Matthieu Resche-Rigon, Jérôme Tamburini, Marion Alcantara, Fabrice Jardin, Etienne Lengliné, Lionel Adès, Didier Bouscary, Ambroise Marçais, Delphine Lebon, Cécile Chabrot, Louis Terriou, Fiorenza Barraco, Anne Banos, Lucile Bussot, Jean-Yves Cahn, Pierre Hirsch, Natacha Maillard, Laurence Simon, Luc-Matthieu Fornecker, Gerard Socié, Regis Peffault de Latour, Flore Sicre de Fontbrune, Adrien Contejean, Matthieu Resche-Rigon, Jérôme Tamburini, Marion Alcantara, Fabrice Jardin, Etienne Lengliné, Lionel Adès, Didier Bouscary, Ambroise Marçais, Delphine Lebon, Cécile Chabrot, Louis Terriou, Fiorenza Barraco, Anne Banos, Lucile Bussot, Jean-Yves Cahn, Pierre Hirsch, Natacha Maillard, Laurence Simon, Luc-Matthieu Fornecker, Gerard Socié, Regis Peffault de Latour, Flore Sicre de Fontbrune

Abstract

Aplastic anemia is a rare but potentially life-threatening disease that may affect older patients. Data regarding the treatment of aplastic anemia in this ageing population remains scarce. We conducted a retrospective nationwide multicenter study in France to examine current treatments for aplastic anemia patients over 60 years old. Our aims were to evaluate efficacy and tolerance, and to analyze predictive factors for response and survival. Over the course of a decade, 88 patients (median age 68.5 years) were identified in 19 centers, with a median follow up of 2.7 years; 21% had very severe and 36% severe aplastic anemia. We analyzed 184 treatment lines, mostly involving the standard combination of anti-thymocyte globulin and cyclosporine-A (33%), which was also the most frequent first-line treatment (50%). After first-line therapy, 32% of patients achieved a complete response, and 15% a partial response. Responses were significantly better in first line and in patients with good performance status, as well as in those that had followed an anti-thymocyte globulin and cyclosporine-A regimen (overall response rate of 70% after first-line treatment). All treatments were well tolerated by patients, including over the age of 70. Three-year survival was 74.7% (median 7.36 years). Age, Charlson comorbidity index and very severe aplastic anemia were independently associated with mortality. Age, per se, is not a limiting factor to aplastic anemia treatment with anti-thymocyte globulin and cyclosporine-A; this regimen should be used as a first-line treatment in elderly patients if they have a good performance status and low comorbidity index score.

Copyright © 2019 Ferrata Storti Foundation.

Figures

Figure 1.
Figure 1.
Overall survival. Causes of death were as follows: nine infections (38%), four hemorrhagic complications (17%), five deaths in palliative care or after active treatment had finished (21%), two cases involving unknown etiologies (8%), one case of clonal evolution to acute myeloid leukemia, one case of multi-metastatic breast cancer, one case of hypercalcemia, and one cardiac arrest. The survival curve (solid line) was obtained using the Kaplan Meier estimator. Dashed lines represent confidence intervals (CI95%).

References

    1. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008;93(4):489–492.
    1. Modan B, Segal S, Shani M, Sheba C. Aplastic anemia in Isreal: evaluation of the etiological role of chloramphenicol on a community-wide basis. Am J Med Sci. 1975;270(3):441–445.
    1. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl. 1996;6023–30.
    1. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518–523.
    1. Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood. 1987;70(6):1718–1721.
    1. Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1990;75(8):1646–1653.
    1. Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med. 1999;130(3):193–201.
    1. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet Lond Engl. 2005;365(9471):1647–1656.
    1. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94(2):264–268.
    1. Yoshizato T, Dumitriu B, Hosokawa K, Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35–47.
    1. Kim S-Y, Lee J-W, Lee S-E, et al. The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis. Genes Chromosomes Cancer. 2010;49(9):844–850.
    1. Kao SY, Xu W, Brandwein JM, et al. Outcomes of older patients (>60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol. 2008;143(5):738–743.
    1. Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. 2017;102(10):1683–1690.
    1. Tichelli A, Marsh JCW. Treatment of aplastic anaemia in elderly patients aged> 60 years. Bone Marrow Transplant. 2013;48(2):180–182.
    1. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
    1. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436.
    1. Shin SH, Jeon YW, Yoon JH, et al. Comparable outcomes between younger (40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Bone Marrow Transplant. 2016;51(11):1456–1463.
    1. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37(1):30–42.
    1. Devillier R, Dalle J-H, Kulasekararaj A, et al. Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. Haematologica. 2016;101(7):884–890.
    1. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48(1):63–70.
    1. Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation (EBMT). Haematologica. 1994;79(5):438–444.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
    1. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
    1. Appelbaum FR, Barrall J, Storb R, et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987;15(11):1134–1139.
    1. Hosokawa K, Sugimori N, Katagiri T, et al. Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8. Eur J Haematol. 2015;95(3):230–238.
    1. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87(7):515–526.
    1. Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81(5):418–422.
    1. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99(9):3129–3135.
    1. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185–1196.
    1. Dufour C, Svahn J, Bacigalupo A. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013;48(2):174–177.
    1. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79(10):2540–2546.
    1. Lengline E, Drenou B, Peterlin P, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103(2):212–220.
    1. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117(17):4434–4441.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel